A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Mitochondrial disorders; Mitochondrial myopathies
  • Focus Therapeutic Use
  • Acronyms MMPOWER-2
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 29 Jun 2017 According to a Stealth BioTherapeutics media release, detailed results from the study were presented at the Mitochondrial Medicine Symposium 2017, the United Mitochondrial Disease Foundation (UMDF) symposium.
    • 29 Jun 2017 Results published in a Stealth BioTherapeutics media release.
    • 15 Jun 2017 According to a Stealth BioTherapeutics media release, top-line results from this study will be presented at the United Mitochondrial Disease Foundation (UMDF) symposium 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top